ArticleBMC cancer2016

Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.

Linh Nguyen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.